Arch Biopartners Inc
XTSX:ARCH

Watchlist Manager
Arch Biopartners Inc Logo
Arch Biopartners Inc
XTSX:ARCH
Watchlist
Price: 1.95 CAD 1.04% Market Closed
Market Cap: 126.1m CAD
Have any thoughts about
Arch Biopartners Inc?
Write Note

Arch Biopartners Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Arch Biopartners Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Arch Biopartners Inc
XTSX:ARCH
Net Income (Common)
-CA$6.1m
CAGR 3-Years
9%
CAGR 5-Years
-25%
CAGR 10-Years
-35%
Abcellera Biologics Inc
NASDAQ:ABCL
Net Income (Common)
-$146.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Replicel Life Sciences Inc
XTSX:RP
Net Income (Common)
-CA$69.3k
CAGR 3-Years
69%
CAGR 5-Years
51%
CAGR 10-Years
N/A
Innovotech Inc
XTSX:IOT
Net Income (Common)
-CA$364.5k
CAGR 3-Years
N/A
CAGR 5-Years
-116%
CAGR 10-Years
7%
No Stocks Found

Arch Biopartners Inc
Glance View

Market Cap
125.3m CAD
Industry
Life Sciences Tools & Services

Arch Biopartners, Inc. operates as a biotechnology company. The company is headquartered in Toronto, Ontario. The firm is focused on the development of technologies that make a medical or commercial impact. Its lead drug candidate Metablok is formed to treat or prevent dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver or kidneys, which often results in organ damage or failure, including in the case of sepsis and corona virus disease-2019 (COVID-19). Its drug candidate also includes AB569, Borg and MetaMx. Its AB569 is a drug candidate for treating antibiotic resistant bacterial infections, primarily in the lungs and wounds. The Borg is a peptide-solid surface Interface for binding of peptides to solid metal and plastic surfaces to inhibit biofilm formation and to reduce corrosion. Its MetaMx is a synthetic molecules that target brain tumor initiating cells and invasive glioma cells.

ARCH Intrinsic Value
0.29 CAD
Overvaluation 85%
Intrinsic Value
Price

See Also

What is Arch Biopartners Inc's Net Income (Common)?
Net Income (Common)
-6.1m CAD

Based on the financial report for Jun 30, 2024, Arch Biopartners Inc's Net Income (Common) amounts to -6.1m CAD.

What is Arch Biopartners Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-35%

Over the last year, the Net Income (Common) growth was -23%. The average annual Net Income (Common) growth rates for Arch Biopartners Inc have been 9% over the past three years , -25% over the past five years , and -35% over the past ten years .

Back to Top